OKT3


Also found in: Wikipedia.

OKT3

An immunosuppressive monoclonal antibody used in organ transplantation.
References in periodicals archive ?
However, since the first mAbs were murine proteins (OKT3 was injected to kidney transplant patients to prevent graft rejection), their repeated administration raised Human Anti Mouse Antibody (HAMA) in the patients that resulted in neutralization of the injected mAb (OKT3).
PBMCs from patients and controls, 2 x [10.sup.6] cells/mL in RPMI with 10% fetal calf serum were incubated at 37[degrees]C and 5% CO2 for three days with PHA and OKT3, and six days with PWM and CMA in triplicate in 96-well plates (Costar, Cambridge, MA).
Purified anti-human CD3 (OKT3) and purified anti-human CD28 (CD28.2) were purchased from eBioscience.
Due to early steroid-resistant vascular rejection, she received treatment with OKT3, and maintenance immunosuppression was switched from cyclosporine to tacrolimus.
The method, in brief, was as follows: for the primary plate coating, 1 [micro]g/ml anti-huCD3 clone OKT3 (eBioscience cat.
Transfected cells were labeled with 2.5 [micro]M Calcein-AM (DOJINDO) for 30 min at 37[degrees]C in Phenol-Redfree Hanks' balanced salt solution, washed twice, and incubated (1 x [10.sup.5]) on Fc-ICAM-1-coated plates, in the absence or presence of 10 [micro]g/mL anti-CD3 Ab (OKT3; Biolegend).
evaluated the prognostic role of expanded activated autologous lymphocytes (EAALS) stimulated by anti-CD3 mAb (OKT3) and IL-2 in GC patients.
Although PCAR without ABMR has no consensus therapy today, induction therapy for PCAR without ABMR commonly consists of not only steroid but also multiple immunosuppressant including deoxyspergualin (DSG) and Muromonab-CD3 (OKT3) [5, 6].
Campsen et al., "The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation," Clinical Transplantation, vol.
Then, PBMC (depleted and non-depleted of [CD69.sup.+] cells) were incubated in 24-well plates (Costar, Corning, NY) precoated with an anti-CD3 (OKT3 clone, 5.0 [micro]g/ml) and an anti-CD28 (clone 28.2, 5.0 [micro]g/ml) for 7 hours at 37[degrees]C with 5% C[O.sub.2], in the presence of an anti CD40L/PE mAb (BD Pharmigen, San Jose, CA, USA).
Induction with OKT3 or IL-2 inhibitor Remuzzi et Journal of American 24 bilateral placement al.
Other risk factors that have been associated with the development of this disease are the use of inducing drugs such as OKT3 (muronamab) and thymoglobulin, anticalcineurinic agents (cyclosporinee, tacrolimus), other viral infections (cytomegalovirus and hepatitis C), among others (3,5).